Abstract
Sildenafil citrate, marketed under the trade name Viagra® by Pfizer Inc., was the first oral pharmacological agent approved by the US Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED), receiving approval on March 27, 1998. A selective inhibitor of phosphodiesterase type 5 (PDE5), sildenafil acts by augmenting the nitric oxide (NO)–cyclic guanosine monophosphate (cGMP) signaling cascade within the smooth muscle of the corpus cavernosum. This review synthesizes preclinical biochemical data, Phase III randomized controlled trial results, FDA pharmacokinetic information, and post-marketing surveillance findings. The compound's ~41% oral bioavailability, 4-hour elimination half-life, and predominantly CYP3A4-mediated hepatic metabolism are discussed alongside its clinically relevant drug interactions, most critically its absolute contraindication with organic nitrates.
1. History of Discovery and Development
The discovery of sildenafil is among the most compelling narratives in modern pharmaceutical history — a story defined not by directed molecular design toward erectile physiology, but by astute clinical observation during an angina study. In 1989, a team of Pfizer scientists at the Sandwich, UK research laboratories, led by Dr. Peter Dunn and Dr. Albert Wood, initiated investigations into a compound designated UK-92,480 (sildenafil) as a potential treatment for hypertension and angina pectoris.
The rationale was rooted in the known vasodilatory effects of nitrates via cGMP elevation. Sildenafil was hypothesized to prolong cGMP signaling by inhibiting its enzymatic degradation. Initial Phase I trials conducted in Merthyr Tydfil, Wales in 1991, however, revealed unexpectedly modest antihypertensive effects insufficient to warrant development as a cardiac agent.
The pivotal moment in sildenafil's history came during drug recall at the conclusion of these early trials. Trial participants — predominantly male — were reluctant to return their remaining tablets. Upon clinical inquiry, a remarkable pattern emerged: subjects reported consistent, drug-associated penile erections. This observation redirected the entire development program toward erectile dysfunction.
Subsequent dedicated Phase II and Phase III trials confirmed sildenafil's efficacy in treating ED across diverse etiologies, including psychogenic, organic, and mixed subtypes. The FDA advisory committee voted unanimously in January 1998 to recommend approval. Formal FDA approval was granted on March 27, 1998, with sildenafil becoming available under the trade name Viagra® — a portmanteau of "vigor" and "Niagara."
1.1 Timeline of Development
Synthesis of UK-92,480 (sildenafil) at Pfizer Sandwich laboratories as a potential angina/hypertension agent
Phase I cardiovascular trials in Wales; observation of penile erection as a notable adverse effect
Development redirected to erectile dysfunction; dedicated Phase II trials initiated
Large-scale Phase III randomized controlled trials demonstrating statistically significant improvements in IIEF scores
FDA approval (March 27, 1998); launch of Viagra® — the world's first oral ED medication
FDA approval for pulmonary arterial hypertension under the trade name Revatio®
US patent expiry; generic sildenafil citrate approved in the United States
2. Mechanism of Action
Sildenafil exerts its pharmacological effect through highly selective, competitive inhibition of phosphodiesterase type 5 (PDE5) — the predominant phosphodiesterase isoenzyme expressed within the smooth muscle of the corpus cavernosum. To understand sildenafil's mechanism fully, it is necessary to first appreciate the physiological cascade that governs penile erection.
2.1 The NO–cGMP Signaling Pathway
Penile erection is fundamentally a neurovascular event mediated by the autonomic nervous system. Sexual stimulation — whether psychogenic or reflexogenic — triggers the release of nitric oxide (NO) from two principal sources: parasympathetic non-adrenergic non-cholinergic (NANC) nerve terminals within the penile vasculature, and vascular endothelial cells.
Once released, NO diffuses into adjacent smooth muscle cells where it activates the enzyme soluble guanylate cyclase (sGC). Activated sGC catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Elevated intracellular cGMP concentrations activate protein kinase G (PKG), which in turn phosphorylates multiple target proteins that collectively reduce intracellular calcium concentration and promote smooth muscle relaxation within the trabeculae of the corpus cavernosum and the helicine arteries.
This relaxation of cavernosal smooth muscle dramatically reduces vascular resistance, facilitating increased arterial inflow from the internal pudendal arteries. Simultaneously, venous outflow is impeded by compression of the subtunical venous plexuses against the non-compliant tunica albuginea — the veno-occlusive mechanism. The resulting increase in intracavernosal pressure, approaching systolic arterial pressure, constitutes the physiological state of erection.
NO–cGMP–PDE5 Pathway: Sildenafil's Point of Action
neurological trigger
NANC neurons + endothelium
GTP → cGMP
smooth muscle relaxation
increased cavernosal blood flow
degrades cGMP → GMP
inhibits PDE5 competitively
Sildenafil's inhibition of PDE5 prevents the hydrolysis of cGMP, amplifying and prolonging smooth muscle relaxation. Critically, this effect is dependent on prior nitric oxide release from sexual stimulation — sildenafil does not produce erections in the absence of arousal.
2.2 PDE5 Inhibition Kinetics
Sildenafil's inhibitory potency against PDE5 is characterized by an IC₅₀ of approximately 3.9 nM, indicating that a concentration of ~3.9 nanomoles per liter is sufficient to inhibit 50% of PDE5 enzymatic activity in vitro. This affinity, while high in absolute terms, is nonetheless approximately 26-fold lower than that of vardenafil (~0.14 nM) and approximately 4-fold lower than that of tadalafil (~0.94 nM).
Sildenafil's selectivity for PDE5 relative to other PDE isoforms is clinically significant. It is approximately 10-fold more selective for PDE5 than PDE6 — an isoform expressed in retinal photoreceptors. This relative lack of PDE6 selectivity (compared to vardenafil) is directly responsible for the visual disturbances (chromatopsia — blue-tinged vision, increased light sensitivity) observed in a subset of patients receiving sildenafil. Sildenafil demonstrates substantially greater selectivity for PDE5 versus PDE1, PDE2, PDE3, and PDE4.
2.3 Dependence on Sexual Stimulation
A fundamental pharmacodynamic property of sildenafil — and indeed all PDE5 inhibitors — is that its erectogenic effect is entirely contingent upon the presence of endogenous sexual stimulation. PDE5 inhibitors do not generate NO; they merely amplify the cGMP signal downstream of NO. In the absence of sexual arousal and the consequent neuronal and endothelial NO release, sildenafil has no discernible proerectile effect in physiological studies. This is a critical distinction from hypothalamic neuropeptide-based erection stimulants, and has important implications for patient education.
3. Pharmacokinetics (ADME Profile)
The pharmacokinetic profile of sildenafil has been extensively characterized in healthy volunteers and patient populations across multiple studies. Understanding the ADME (absorption, distribution, metabolism, excretion) characteristics is essential for predicting clinical response, dosing intervals, and drug interaction potential.
AAbsorption
Sildenafil is rapidly absorbed from the gastrointestinal tract following oral administration. Maximum plasma concentrations (Cmax) are achieved within 30 to 120 minutes (median: 60 minutes) under fasted conditions. The absolute oral bioavailability averages approximately 41% (range: 25–63%), reflecting significant first-pass hepatic metabolism.
Food Effect: High-fat meals delay the time to peak plasma concentration (Tmax) by approximately 60 minutes and reduce Cmax by approximately 29%. While the extent of absorption (AUC) is not significantly affected, patients requiring rapid onset of action are generally advised to take sildenafil on an empty stomach or after a light, low-fat meal.
DDistribution
The mean steady-state volume of distribution for sildenafil is approximately 105 liters, indicating extensive tissue distribution beyond the plasma compartment. Sildenafil and its active N-desmethyl metabolite (UK-103,320) are both highly bound to plasma proteins (~96%), primarily albumin and alpha-1 acid glycoprotein.
Sildenafil does not cross the blood-brain barrier to a clinically meaningful extent under standard dosing conditions. It is not detected in the semen of treated men at pharmacologically relevant concentrations, and poses no risk of pharmacological effect in sexual partners.
MMetabolism
Sildenafil is primarily metabolized in the liver by cytochrome P450 isoenzymes, with CYP3A4 being the major pathway (approximately 80%) and CYP2C9 contributing as a minor pathway. The principal metabolite is N-desmethyl sildenafil, which circulates at concentrations approximately 40% of the parent compound and retains approximately 50% of the PDE5 inhibitory potency, contributing meaningfully to the overall pharmacodynamic effect.
The N-desmethyl metabolite undergoes further oxidative metabolism, ultimately yielding inactive products that are excreted. Hepatic impairment significantly elevates sildenafil plasma concentrations, necessitating dose adjustments in patients with compromised hepatic function.
EExcretion
Following oral or intravenous administration, sildenafil is predominantly excreted as metabolites in the feces (~80%) with a smaller proportion in urine (~13%). The terminal elimination half-life (t½) of sildenafil averages approximately 4 hours, with the N-desmethyl metabolite exhibiting a similar half-life of approximately 4 hours.
Renal impairment (creatinine clearance <30 mL/min) reduces sildenafil clearance, resulting in approximately 100% increases in AUC and Cmax. Elderly patients (>65 years) exhibit higher plasma sildenafil exposures (~90% greater AUC) due to reduced clearance, potentially requiring dose reduction.
3.1 Key Pharmacokinetic Parameters (Summary)
| Parameter | Value (Fasted, 100 mg) | Clinical Significance |
|---|---|---|
| Oral Bioavailability (F) | ~41% | Moderate; first-pass effect significant |
| Tmax | 0.5–2 hours (median 1 hr) | Dose ~1 hour before sexual activity |
| Elimination Half-Life (t½) | ~4 hours | Duration of effect ~4–6 hours |
| Volume of Distribution (Vd) | ~105 L | Extensive tissue distribution |
| Protein Binding | ~96% | High; interaction risk with other highly-bound drugs |
| Primary Metabolism | CYP3A4 (major), CYP2C9 | Multiple CYP3A4 drug interactions |
| Primary Route of Excretion | Fecal (~80%) | Adjust dose in hepatic impairment |
4. Clinical Efficacy: Landmark Trial Data
The clinical efficacy of sildenafil in erectile dysfunction has been established across an extensive body of randomized, double-blind, placebo-controlled trials enrolling thousands of patients spanning diverse etiological subtypes. The primary efficacy endpoints across these trials have consistently utilized the International Index of Erectile Function (IIEF), specifically the Erectile Function (EF) domain score, and the per-patient proportion of successful intercourse attempts.
4.1 Pivotal Phase III Registration Trials
The seminal Phase III publication by Goldstein et al. (1998) in the New England Journal of Medicine — enrolling 532 men with broadly inclusive ED etiology (organic, psychogenic, and mixed) — demonstrated that sildenafil at doses of 25 mg, 50 mg, and 100 mg produced statistically significant and dose-dependent improvements over placebo across all IIEF domains. The percentage of successful attempts at intercourse was 69% at 100 mg versus 22% in the placebo group — a clinically and statistically robust difference (p < 0.001).
Critically, this efficacy has been replicated in patient subpopulations presenting particular therapeutic challenges: men with type 1 and type 2 diabetes mellitus (Rendell et al., 1999; N=268; response rate 56% vs. 10% placebo), men with spinal cord injury, and men following radical prostatectomy with nerve-sparing technique (Zippe et al., 2000). These data collectively confirm sildenafil's clinical utility across the broad spectrum of erectile dysfunction pathophysiology.
4.2 Responder Rates by Etiology
| ED Etiology | Sildenafil Response Rate | Placebo Response Rate |
|---|---|---|
| Broadly inclusive (mixed etiology) | ~69% | ~22% |
| Diabetes mellitus | ~56% | ~10% |
| Spinal cord injury | ~75% | ~7% |
| Post radical prostatectomy (nerve-sparing) | ~43% | ~15% |
| Cardiovascular disease | ~70% | ~20% |
Compiled from FDA prescribing information and Goldstein I et al. (1998) N Engl J Med, Rendell MS et al. (1999) JAMA, and related Phase III publications. Values represent approximate published rates.
5. Adverse Effect Profile
Sildenafil's adverse effects are largely predictable from its pharmacodynamic mechanism. As a vasodilatory agent acting via cGMP elevation, most adverse effects represent extensions of its primary pharmacological action in tissues expressing PDE5 or PDE6.
In the pooled Phase III trial safety population, the most frequently reported adverse events were: headache (~16%), flushing (~10%), dyspepsia (~7%), nasal congestion (~4%), and visual disturbances (~3%). These effects are dose-dependent, transient, and typically mild to moderate in severity. Visual disturbances — characterized by transient altered color perception or increased sensitivity to light — arise from PDE6 inhibition in retinal rod photoreceptors, where cGMP also serves as a second messenger in phototransduction.
Common Adverse Effects (≥2%)
- Headache~16%
- Flushing/vasodilation~10%
- Dyspepsia~7%
- Nasal congestion~4%
- Dizziness~4%
- Visual disturbances (chromatopsia)~3%
Critical Safety Considerations
- ! Absolute contraindication with organic nitrates: Concurrent use produces life-threatening, potentially fatal hypotension via additive cGMP accumulation. This contraindication is absolute and unconditional.
- ! Non-arteritic anterior ischemic optic neuropathy (NAION): Rare post-marketing reports of sudden vision loss in one eye. Patients with risk factors (prior NAION, "disc at risk" anatomy) should be evaluated with caution.
- ! Hearing impairment: Rare cases of sudden hearing loss reported post-marketing; causality not definitively established but warrants monitoring.
- ! Priapism: Prolonged erections (>4 hours) have been reported, particularly in patients with predisposing anatomical or hematological conditions (sickle cell disease, multiple myeloma, leukemia). Requires immediate medical attention to prevent permanent tissue damage.
6. Drug Interactions
Drug interactions with sildenafil arise through two principal mechanisms: pharmacodynamic interactions (additive vasodilatory effects) and pharmacokinetic interactions (CYP3A4-mediated alterations in sildenafil plasma concentrations).
6.1 Pharmacodynamic Interactions
- CONTRAINDICATED:All organic nitrates and nitric oxide donors (isosorbide mononitrate, isosorbide dinitrate, nitroglycerin) — risk of severe hypotension
- CAUTION:Alpha-adrenergic blockers (tamsulosin, doxazosin) — additive antihypertensive effect; initial doses should be separated
- CAUTION:Antihypertensive agents — additive blood pressure-lowering effect
6.2 Pharmacokinetic Interactions (CYP3A4)
- STRONG CYP3A4 inhibitors(ritonavir, ketoconazole, itraconazole, clarithromycin) — markedly increase sildenafil AUC; dose reduction to 25 mg recommended or use is contraindicated
- MODERATE CYP3A4 inhibitors(erythromycin, saquinavir, amprenavir) — increase sildenafil AUC; dose adjustment may be required
- CYP3A4 inducers(rifampin, carbamazepine, phenytoin) — reduce sildenafil plasma concentrations; may reduce efficacy
Further Research: Comparative Pharmacology
Sildenafil is best understood in the context of the broader PDE5 inhibitor class. The following comparative resources are available within this institute's research compendium: